Atogepant
Clinical data | |
---|---|
Trade names | Qulipta |
Other names | AGN-241689, MK-8031 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C29H23F6N5O3 |
Molar mass | 603.525 g·mol−1 |
3D model (JSmol) | |
| |
|
Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.[1][2]
It was approved for medical use in the United States in September 2021.[1][3]
References[]
- ^ a b c "Qulipta- atogepant tablet". DailyMed. Retrieved 31 October 2021.
- ^ Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?". Current Opinion in Neurology. 33 (3): 309–315. doi:10.1097/WCO.0000000000000806. PMID 32251023. S2CID 215408433.
- ^ "FDA Approves Qulipta (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine". AbbVie (Press release). 28 September 2021. Retrieved 29 September 2021 – via PR Newswire.
External links[]
- "Atogepant". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- AbbVie brands
- Antimigraine drugs
- Calcitonin gene-related peptide receptor antagonists
- Carboxamides
- Organofluorides
- Piperidines
- Pyridines
- Pyrroles
- Spiro compounds
- Analgesic stubs